Schedule 13G ownership disclosure
Viking Therapeutics Inc
Common Stock · CUSIP: 92686J106
Event date: 2024-12-31
- Filing-level shares
- 5,872,642
- Percent of class
- 5.3%
- BlackRock, Inc.
Shares: 5,872,642 · Class: 5.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002012383-25-000647
- Form type
- SCHEDULE 13G
- Filer
- BlackRock, Inc.
- CIK
- CIK 2012383
- Filed
- Feb 04, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership